GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Cabotegravir / rilpivirine - CABENUVA intramuscular kit

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Cabenuva - labeled renal guidance

Product / population
Cabotegravir/rilpivirine (Cabenuva), long-acting IM injection kit
Renal method
Creatinine clearance (CrCl), mL/min
Source revision
DailyMed SPL version 16, posted Dec 05, 2025
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Retain the increased-monitoring instruction in severe renal disease

CABENUVA specifies additional adverse-effect monitoring in severe impairment and ESRD. The RX retrieval failed; this addition is official-label content.

What to reconcile: Confirm HIV-treatment eligibility and injection schedule; do not replace this instruction with APRETUDE wording.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references

Cabenuva - product and source limitations

Verify the long-acting injectable regimen and the instructions for missed doses.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Cabenuva - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Cabotegravir/rilpivirine (Cabenuva), long-acting IM injection kit

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 16, posted Dec 05, 2025
Retrieved: 2026-11-07

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

At CrCl 30 to below 90 mL/min no renal adjustment is required for the long-acting injection combination. With severe impairment or ESRD, increase monitoring for adverse effects. Verify the long-acting injectable regimen and the instructions for missed doses.

RDM74-cabenuva-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1698baf3-f895-4c42-a1b1-e9ee3f20da36
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 16, posted Dec 05, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
3323097dbb8b80e6b0c7f25b2791d9950c4787fb6f66e4ff063f5392a1d354f1

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=cabotegravir-rilpivirine-cabenuva&s1=RDM74-cabenuva-official&h1=a483e5fd38cb7d08910b22d017e2f614e3989521976b4d7305d94b65ed64fc80

Top